

What does BARDA do for global health R&D?

The Biomedical Advanced Research and Development Authority (BARDA) supports the development of vaccines, drugs, and other medical countermeasures (MCMs) to protect Americans against threats to public health, including emerging infectious diseases, pandemic influenza, and antimicrobial resistance (AMR).

Why is BARDA's role in global health R&D important?

BARDA works with industry and other partners to bridge the "valley of death" between basic research and product development, where research and development (R&D) efforts most often fail. Through unique contracting and incentive mechanisms, BARDA's partnerships ensure promising research is translated into urgently needed medical products by creating commercial incentives for developers that would otherwise not exist. During the COVID-19 pandemic, BARDA's prominence and funding grew exponentially as the agency was charged with leading the US government's MCM R&D portfolio, demonstrating how—with sufficient, sustained funding—BARDA is uniquely equipped to advance products against a range of other global health threats.


Impact of investment

BARDA support has helped advance at least:

45 approved/authorized products for COVID-19

7 approved/authorized products for Ebola and Zika

R&D investment by health area



2018-2022 G-FINDER data. Does not reflect investments in antimicrobial resistance or influenza.

R&D SUCCESS STORIES



COVID-19

Led US **COVID-19 product development** efforts for vaccines, diagnostics, and therapeutics, including advancing all therapeutics and first-generation vaccines approved or authorized by the US Food and Drug Administration (FDA).



EBOLA

Development of both **Ebola Zaire vaccines**, as well as **two Ebola treatments** and **one rapid diagnostic test** approved by FDA.



AMR

Accelerating **antibacterial research** through the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, public-private partnership, which has advanced **2 available diagnostics** and supported **100 projects in 13 countries**, to build the **world's largest early development pipeline of antibacterial innovations**.



MPOX

Development of the only FDA-approved **vaccine for smallpox/mpox**, which was deployed during the 2022-2023 outbreak.



ZIKA

Development of **Zika diagnostics**, including tests to **identify infection** and **screen blood supplies**.



INFLUENZA

Strengthening manufacturing capacity in low- and middle-income countries to enable rapid production of seasonal and **pandemic influenza vaccines**.